Literature DB >> 17922725

Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study.

N Celebisoy1, F Gökçay, H Sirin, O Akyürekli.   

Abstract

OBJECTIVES - To assess the efficacy of topiramate in the treatment of idiopathic intracranial hypertension (IIH) and to compare it with acetazolamide. METHODS - Fourty patients diagnosed as IIH and randomly assigned to treatment with either acetazolamide or topiramate were assessed prospectively. Improvement in the visual fields at the end of third, sixth and twelfth months were taken into consideration. RESULTS - The demographic, clinical features and the cerebrospinal fluid (CSF) pressure of the two treatment groups were similar at the beginning of the study. When the follow-up visual field grades were compared with the visual field grades at the beginning of the study in each group a statistically significant improvement was detected with both drugs. When the results of the two treatment groups were compared with each other no statistically significant difference was present. Prominent weight loss was recorded in the topiramate group. CONCLUSIONS - Topiramate seems to be effective in the treatment of IIH. Weight reduction as well as the reduction of the CSF formation is the possible mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922725     DOI: 10.1111/j.1600-0404.2007.00905.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  77 in total

1.  Inhibition of carbonic anhydrase reduces brain injury after intracerebral hemorrhage.

Authors:  Fuyou Guo; Ya Hua; Jinhu Wang; Richard F Keep; Guohua Xi
Journal:  Transl Stroke Res       Date:  2012-03       Impact factor: 6.829

Review 2.  Sinus venous stenosis, intracranial hypertension and progression of primary headaches.

Authors:  Roberto De Simone; Angelo Ranieri; Silvana Montella; Mario Marchese; Pasquale Persico; Vincenzo Bonavita
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

Review 3.  [Characteristic neurological features, differential diagnostic criteria and medicinal treatment of idiopathic intracranial hypertension].

Authors:  K-D Willenborg; W Nacimiento
Journal:  Ophthalmologe       Date:  2015-10       Impact factor: 1.059

Review 4.  [Idiopathic intracranial hypertension].

Authors:  J Bäuerle; K Egger; A Harloff
Journal:  Nervenarzt       Date:  2017-02       Impact factor: 1.214

Review 5.  Current concepts and strategies in the diagnosis and management of idiopathic intracranial hypertension in adults.

Authors:  Jane W Chan
Journal:  J Neurol       Date:  2017-01-31       Impact factor: 4.849

Review 6.  Is idiopathic intracranial hypertension without papilledema a risk factor for migraine progression?

Authors:  Roberto De Simone; Angelo Ranieri; Chiara Fiorillo; Leonilda Bilo; Vincenzo Bonavita
Journal:  Neurol Sci       Date:  2010-02-25       Impact factor: 3.307

Review 7.  Primary Stabbing Headache.

Authors:  Danielle Murray; Esma Dilli
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-08       Impact factor: 5.081

8.  The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.

Authors:  Michael Wall; Mark J Kupersmith; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Michael P McDermott
Journal:  JAMA Neurol       Date:  2014-06       Impact factor: 18.302

Review 9.  Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders.

Authors:  Michael J Marmura; Aliza S Kumpinsky
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

10.  Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study.

Authors:  Alexandra J Sinclair; Michael A Burdon; Peter G Nightingale; Alexandra K Ball; Peter Good; Timothy D Matthews; Andrew Jacks; Mark Lawden; Carl E Clarke; Paul M Stewart; Elizabeth A Walker; Jeremy W Tomlinson; Saaeha Rauz
Journal:  BMJ       Date:  2010-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.